ENETS 2011
Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors

Guest Editors
Ramon Salazar, Barcelona
Bertram Wiedenmann, Berlin
Philippe Ruszniewski, Clichy
Neuroendocrinology publishes papers reporting original research in basic and clinical neuroendocrinology. The journal explores the complex interactions between neuronal networks and endocrine glands (in some instances also immune cells) in both central and peripheral nervous systems. Original contributions cover all aspects of the field, from molecular and cellular neuroendocrinology, physiology, pharmacology, and the neuroanatomy of neuroendocrine systems to neuroendocrine correlates of behaviour, clinical neuroendocrinology and neuroendocrine cancers. Readers will also benefit from reviews by noted experts, which highlight especially active areas of current research, and special focus editions of topical interest.

More information at www.karger.com/nen
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Neuroendocrinology
2012: Volumes 95-96
4 issues per volume
Language: English
ISSN 0028–3835 (print)
ISSN 1423–0194 (online)

Listed in bibliographic services, including Current Contents®/Life Sciences, PubMed/MEDLINE, Biological Abstracts
International Journal for Basic and Clinical Studies on Neuroendocrine Relationships

Founded 1965 by E. Bajusz

Official Journal of
International Neuroendocrine Federation (INF)
European Neuroendocrine Association (ENEA)
European Neuroendocrine Tumor Society (ENETS)

Editor-in-Chief
R.P. Millar, Edinburgh

Editorial Manager
A. Ross, Edinburgh

Editors
I.J. Clarke, Clayton, Vic.
C. Coen, London
M.A. Cowley, Clayton, Vic.
A. Douglas, Edinburgh
A. Enjalbert, Marseille
A.B. Grossman, Headington
D. Jezová, Bratislava
M.J. Kelly, Portland, Oreg.
P.A. Kelly, Paris
S.R. Ojeda, Beaverton, Oreg.
(Reviews)
G. Rindi, Rome
M. Tena-Sempere, Cordoba
B. Wiedenmann, Berlin

Editorial Board
H. Ahlman, Gothenburg
E. Arzt, Buenos Aires
T. Bartness, Atlanta, Ga.
C.L. Bethea, Beaverton, Oreg.
D.W. Brann, Augusta, Ga.
B. Canny, Monash, Vic.
M. Caplin, London
K. Catt, Bethesda, Md.
A. Chodobski, Providence, R.I.
W. de Herder, Rotterdam
S.L. Dickson, Gothenburg
J. Drouin, Montreal, Que.
P.J. Enriori, Monash, Vic.
W. Farrell, Keele
M. Freeman, Tallahassee, Fla.
R.C. Gaillard, Lausanne
A.C. Gore, Austin, Tex.
K. Grove, Beaverton, Oreg.
T. Harmar, Edinburgh
A. Herbison, Dunedin
J. Herman, Cincinnati, Ohio
J.J. Hirst, Callaghan, N.S.W.
T. Hökfelt, Stockholm
A. Kauffman, La Jolla, Calif.
K. Kim, Seoul
J.Z. Kiss, Geneva
A.C. Latronico, São Paulo
G. Leng, Edinburgh
J. Levine, Evanston, Ill.
C. Libertun, Buenos Aires
C. Llorens-Cortes, Paris
A. Loudon, Manchester
Z.-L. Lu, Edinburgh
G. Martinez de la Escalera,
Querétaro
R. Melcangi, Milano
I. Modlin, New Haven, Conn.
Z. Naor, Tel Aviv
M. Palkovits, Budapest
I. Parhar, Kuala Lumpur
D.W. Pfaff, New York, N.Y.
T.M. Plant, Pittsburgh, Pa.
J. Reul, Bristol
R. Reynolds, Edinburgh
E. Riísmans, Charlottesville, Va.
J.L. Roberts, San Antonio, Tex.
I. Robinson, London
P. Ruszniewski, Clichy
W. Schlegel, Geneva
D. Skinner, Laramie, Wyo.
E. Spinedi, La Plata
R. Steiner, Seattle, Wash.
E. Terasawa, Madison, Wisc.
A. Tilbrook, Roseworthy, S.A.
W. Vale, La Jolla, Calif.
B. Walker, Edinburgh
H. Watanobe, Chiba
M. Wierman, Denver, Colo.
J. Wingfield, Seattle, Wash.
S. Wray, Bethesda, Md.
Guidelines for Authors

The Editorial Board of Neuroendocrinology welcomes articles for review that report new observations on interactions between the brain and the endocrine system. Papers that are published deal with both basic and clinical subjects.

Editors, summaries of meetings, and reviews of timely topics in basic and clinical neuroendocrinology are also published, but these items are accepted only at the invitation of the Editor-in-Chief.

Submission
Manuscripts written in English should be submitted using the online submission website at:
www.karger.com/nen
or as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:
editor@nen-edinburgh.org

Editorial Office 'Neuroendocrinology'
Prof. Dr. Robert Millar
South Lodge
295 Gilmerton Road
Edinburgh EH16 5UL (UK)
Tel. +44 131 208 0769
Editorial Manager
Dr. Allison Ross
editor@nen-edinburgh.org

Manuscripts should contain unpublished results of research work, and should be as concise as possible. The following presentation is recommended: Abstract, Introductory statement on the purpose of the studies, Materials and methods, Results, Discussion, and References. Current abbreviations should be used throughout the text and tables (for pituitary hormones: ACTH, Th-END, FSH, GH, LH, TSH; for neuropeptides: CRH, nor CRF; GAL, GHRH, not GRF; GnRH, not LH RH; NPY, NT, SRIF, not SRIF; VIP...), and a definition should be provided the first time each abbreviation appears. Please limit alternative names to those in common use, and avoid other abbreviations and acronyms. Manuscripts should contain novel, original data. As a rule, the Editorial office commits itself to achieve initial review of manuscripts within less than 60 days, average interval between submission and publication is 7-9 months. Authors of articles reporting mostly confirmatory, fragmentary or preliminary findings may be notified within 2 weeks that their manuscript will not be submitted to formal review. Such a proposal will be made by the associate editors assisted by one member of the Editorial Board. This procedure is intended to provide rapid feedback to authors of manuscripts which have a poor chance of being accepted. Authors have the opportunity to appeal against the decision. Contributing authors should know that one of the criteria considered in reviewing manuscripts is the humane and proper treatment of animals. The editors realize that the use of anesthetics, analgesics, and tranquilizers would defeat the purpose of some experiments. However, the use of painful or otherwise noxious stimuli must be carefully and thoroughly justified in the paper. Papers that do not meet these criteria will not be accepted for publication.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Neuroendocrinology' and may not be reproduced by any means, in any form, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Arrangement
Title page: The first page of each paper should carry the title, the authors' full and last names, and the name of the institute or department where the authors conducted their research work. In addition, the following should be put on the title page. 1. A short title for use as a running head. 2. A list of 3–9 key words that reflect the content of the paper. 3. The name and complete mailing address as well as phone and fax numbers and e-mail address of the individual to whom correspondence, proofs, and requests for reprnts should be addressed.

Abstract: Each paper must have a short abstract describing procedures, observations and conclusions, which will appear at the beginning of the article. Abstracts should not exceed 250 words.

Footnotes: Avoid footnotes if at all possible. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.

Acknowledgments: Including, where relevant, credit to the sources of grant support.

Tables and illustrations: Tables (numbered in Arabic numerals) should be prepared on separate pages, and each should have a suitable heading. Illustrations should be numbered in Arabic numerals and legends for the figures should be submitted on a separate page. For the reproduction of illustrations, only good drawings and original photographs can be accepted, negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When preparing illustrations, please allow generous margins on one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a resolution of 300 dpi after scaling, line drawings one of 800–1200 dpi.

References: In the text identify references by Arabic numerals (in square brackets). Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of all the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples:
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
Papers that have been submitted to a journal but are not yet accepted should not be listed in the bibliography, but the data in them can be referred to in the text as unpublished observations. If details of meta-data are only available in papers that are 'in press', copies of the papers should be included with the manuscript submitted to 'Neuroendocrinology', so that the editorial referees can have adequate information to judge the manuscript.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author’s_choice.

NIH-Funded Research
All articles for which NIH funds were received are published electronically ahead of print with a DOI number and are supplemented later with the definitive reference of the printed version. The articles become available immediately after the authors' approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
Order forms and a price list are sent with the PDF. Orders submitted after the issue is printed are subject to considerably higher prices.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (mov, avi, mpg).
General Information

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

- **Print or Online**: CHF 1618.– EUR 1294.– USD 1572.00
- **postage and handling**: CHF 54.40 Europe, CHF 80.– Overseas

**Institutional subscription:**

- **Print or Online**: CHF 3236.– EUR 2588.– USD 3142.00
- **postage and handling**: CHF 68.– Europe, CHF 100.– Overseas

**Airmail surcharge**: CHF 68.– / USD 64.00

Discount subscription prices:

- Int. Neuroendocrine Federation
- Europ. Neuroendocrine Association

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.ch.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc.

Karger China
10th Floor, Twin Towers (East)
B12 Jianggunwen Avenue
Beijing 100022
China
t: +86 10 5123 5033
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

Karger Regional Office (Malaysia)
CEO Suite Kuala Lumpur
Quill 2, 27th Floor
Jalan Stesen Sentral 5
KL Sentral
Kuala Lumpur 50470
Malaysia
t: +60 3 2776 6803
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

Japan
Karger Japan, Inc.
Shiba Daimon, Asahi Bldg., 2F
1-2-3 Shiba Daimon
Minato-ku
Tokyo 105-0012
Japan
t: +81 3 6435 6242
e: publisher@karger.jp
w: www.karger.jp

South East Asia, China and Taiwan
Karger Region Office (Malaysia)
CEO Suite Kuala Lumpur
Quill 2, 27th Floor
Jalan Stesen Sentral 5
KL Sentral
Kuala Lumpur 50470
Malaysia
t: +60 3 2776 6803
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

Orders can be placed at agencies, bookstores, directly with the Publisher or further Karger offices or representatives:

- **S. Karger AG**
  Medical and Scientific Publishers
  P.O. Box
  CH–4055 Basel
  (for courier services only: Allschwilerstrasse 10
  CH–4055 Basel)
t: +41 61 306 11 11
e: karger@karger.ch
w: www.karger.com

- **Karger Regional Office (Malaysia)**
  CEO Suite Kuala Lumpur
  Quill 2, 27th Floor
  Kuala Lumpur 50470
  Malaysia
t: +60 3 2776 6803
e: service@karger.cn; r.chew@karger.cn
w: www.karger.cn

Subscription to this journal is regularly listed in bibliographic services, including Current Contents and PubMed/MEDLINE.

Change of Address:
Both old and new address should be sent to the subscription source.

KARGER
© 2012 S. Karger AG, Basel
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

The Journal Home Page is available at: www.karger.com/nen
Welcome to
ESPE 2012 in Leipzig

Theme: Translating Science into Clinical Practice

For registration and further information: www.espe2012.org
Contents

See the journal website for contents
The Eleventh International Symposium on Neurobiology and Neuroendocrinology of Aging will be held July 29 to August 3, 2012 in the Kloster Mehrerau, Bregenz, Austria. The symposium is part of a biennial series that started in 1992. It will be held in a format similar to the Gordon Conferences, with morning and evening sessions Monday–Thursday. Afternoons will be free for informal, individual discussions or simply to enjoy the beautiful surroundings of Bregenz (glimpses of which are sprinkled throughout the website). For the 2012 Symposium, the organizers are joining forces with the ongoing European Framework Program 7 project MARK-AGE, which is focused on the establishment of biomarkers of human aging (www.mark-age.eu). Thus, the Symposium will serve as a platform for the 2012 MARK-AGE Summer School. In order to maximize the value of the conference for students and ‘newcomers’ to gerontology, an introduction to the field will be given on Sunday afternoon.

Program Committee
Alexander Bürkle, Konstanz, Germany
Aimin Bao, Hangzhou, China
Günter Lepperdinger, Innsbruck, Austria
Roberto Melcangi, Milan, Italy
Marie-Christine Pardon, Nottingham, UK
George Roth, Baltimore, MD, USA
Jay Zimmerman, Cold Spring-on-Hudson, NY, USA

Organizing Chair
Holly Brown-Borg, University of North Dakota, USA

Scientific Secretary
Michael Ramek, Graz, Austria

Deadlines
Early registration discount March 1, 2012
Registration and poster abstract submission May 1, 2012

All registered participants will receive the 2012 Proceedings as part of their registration fee.

For further details please visit www.neurobiology-and-neuroendocrinology-of-aging.org

www.mark-age.eu
Second World Conference of Kisspeptin Signaling in the Brain

TOKYO JAPAN 2012

November 6 (Tue) - 9 (Fri), 2012

http://www.kp2012.jp/

secretariat@kp2012.jp

Local Organizing Committee
Kotaro Mada (University of Tokyo)
Yoshihiko Oka (University of Tokyo)
Hiromichi Nakamura (National Institute for Aging)
Mitsuko Osawa (Kagoshima University)
Mitsuo Sakai (Tokushima University)
Shinya Oishi (University of Tokyo)
Hitoshi Tsukada (University of Tokyo)
Shinya Oishi (University of Tokyo)
Yuji Iwata (Tokyo Medical University)
Yasuo Katsumi (University of Tokyo)
Masayuki Nishihara (University of Tokyo)
Masayuki Ishii (University of Tokyo)
Yoshito Yonashisaka (Ehime University)
Toshio Hishiki (Takara-Shuzo Co., Ltd.)

Scientific Advisory Board
Kotaro Mada (University of Tokyo)
Manuel Tendeiro (University of Córdoba)
Robert A. Stohler (University of Washington)
Allan P. Herring (University of California, San Francisco)
Janet S. Clarke (University of Washington)
Stephanie S. Seminara (UCSF)
Terry H. Plant (University of Pittsburgh)
Nicola de Krey (University of Leiden)
Yoshihiko Oka (University of Tokyo)
Suzanne M. Meehan (University of Michigan)
Alexander S. Kaufman (UCSD)
Victor M. Navarro (University of Cordoba)
Jeremy R. Smith (University of Michigan)
Mitsuo Sakai (University of Tokyo)
P. J. Tews (University of Wisconsin)
Kevin Y. O’Byrne (King’s College London)
Toshio Hishiki (Takara-Shuzo Co., Ltd.)
William H. Colledge (University of Cambridge)
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of ensuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

Selected contributions

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer: Stemmler, H.-J.; Harbeck, N. (Munich); Gröll de Rivera, I. (Ebersberg); Vehling Kaiser, U. (Landshut); Rauthe, G. (Obenaufen); Abenhart, W.; Artmann, A.; Sommer, H. (Munich); Meerpohl, H.-G.; Karienleh; Kiechel, M.; Heinemann, V. (Munich)


Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer: Heinemann, V. (Munich); Hoff, P.M. (São Paulo)


Cisplatin Application in Pregnancy: First in vivo Analysis of 7 Patients: Marnitz, S.; Köhler, C. (Berlin); Oppelt, P. (Linz); Schmittel, A.; Favero, G.; Hasenbein, K.; Schneider, A. (Berlin); Markman, M. (Houston, Tex.)


A Randomized Phase II Study Comparing Two Schedules of the 21-Day Regimen of Gemcitabine and Carboplatin in Advanced Non-Small Cell Lung Cancer: Surmont, V. (Rotterdam/Gent); Aerts, J.G.V. (Bever); van Klaveren, R.J. (Rotterdam); Tournoy, K. (Ghent); Tan, K.Y.; Verhout, R.M.; Schmitz, P.I.M. (Rotterdam); Legrand, C. (Louvain-la-Neuve); Hoogsteden, H.C. (Rotterdam); van Meerbeek, J.P. (Ghent)

More information at www.karger.com/ocl

• Pay-per-View and Subscriber Access to Full Text
• Full Table of Contents
• Full Editorial Board
• Free Abstracts and Selected Articles
• Online Sample Issue
• Submission/Guidelines for Authors
• Subscription Details
• Free Alert Service
• Online Library Recommendation

Oncology 2012: Volumes 82, 83
6 issues per volume
Language: English
ISSN 0030–2414 (print)
ISSN 1423–0232 (online)

Listed in bibliographic services, including Current Contents®/Life Sciences, MEDLINE, Biological Abstracts, EMBASE/Excerpta Medica
Contents
Preface
Neuroendocrine Interactions in the Thymus: From Physiology to Therapy: Savino, W.; Dardenne, M. on behalf of Fiocruz/CNRS International Associated Laboratory of Immunology and Immunopathology
Evidence of Conserved Neuroendocrine Interactions in the Thymus: Intrathymic Expression of Neuropeptides in Mammalian and Non-Mammalian Vertebrates: Silveira, A.B.; Palma, D.B.

Age-Associated Remodeling of Neural and Nonneural Thymic Catecholaminergic Network Affects Thymopoietic Productivity: Leposavić, G.; Pilipović, I.; Perišić, M.
Growth Hormone Is a Modulator of Lymphocyte Migration: Smania-Soto, S.; Alves-Martins-Neto, A.; Dardenne, M.; Savino, W.
Intercommunication between the Neuroendocrine and Immune Systems: Focus on Myasthenia Gravis: Mays, J.; Butts, C.L.

The Role of the Sympathetic Nervous System in the Thymus in Health and Disease: Roggero, E.; Besedovsky, H.O.; del Rey, A.

Author Index/Subject Index
Digestion concentrates on clinical research reports: in addition to editorials and reviews, sections on Stomach/Esophagus, Bowel, Neuro-Gastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology are managed by carefully selected Associate Editors. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal's coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.

Selected contributions

Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan: Sakamoto, C. (Tokyo); Soen, S. (Nara)

Obesity Affects the Liver — The Link between Adipocytes and Hepatocytes: Wree, A.; Kahraman, A.; Gerken, G.; Canbay, A. (Essen)


Role of DNA Methylation in the Development of Diffuse-Type Gastric Cancer: Yamamoto, E.; Suzuki, H.; Takamaru, H.; Yamamoto, H.; Toyota, M.; Shinomura, Y. (Sapporo)

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis: Schütte, K.; Zimmermann, L.; Bornschein, J.; Csepreghi, A.; Rühl, R.; Rieke, J.; Mallerheiner, P. (Magdeburg)


ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors

This special issue of Neuroendocrinology provides the updated and revised version of the previously published and most cited ENETs guidelines. It is the final product of a three-day consensus meeting held in Barcelona where old and recent data on new evidence and insights, were intensely discussed in working group and plenary sessions. Each paper covers the topics of epidemiology, prognosis, clinical presentation, imaging, laboratory tests, pathology and genetics, therapeutic strategies and follow-up recommendations for each neuroendocrine tumor of the gastrointestinal tract and pancreas. Notes were taken continuously so that the final agreement on each question was noted and returned to each session chair for preparation of the consensus statements and papers. The consensus sessions covered the following neuroendocrine neoplasm-related topics by sites of origin or stage: gastroduodenal, hindgut, functional pancreatic, non-functional pancreatic, midgut (including appendix), and a final session that covered liver and other distant metastases from neuroendocrine neoplasms of any origin.